Full Text Journal Articles by
Author David E Gyorki

Advertisement

Find full text journal articles






Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy.

B Mark Smithers, Robyn P M Saw, David E Gyorki, Richard C W Martin, Victoria Atkinson, Andrew Haydon, Rachel Roberts-Thomson, John F Thompson,

Australia and New Zealand have the highest incidence and mortality rates for melanoma in the world. Local surgery is still the standard treatment of primary cutaneous melanoma, and it is therefore important that surgeons understand the optimal care pathways for patients with melanoma. Accurate staging is critical to ensure a ... Read more >>

ANZ J Surg (ANZ journal of surgery)
[2021, 91 Suppl 2:3-13]

Cited: 0 times

View full text PDF listing >>



ASO Author Reflections: Standardization in the Management of Retroperitoneal Sarcoma Through International Collaboration.

David E Gyorki, Christina L Roland,

Ann Surg Oncol (Annals of surgical oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Ptpn2 and KLRG1 regulate the generation and function of tissue-resident memory CD8+ T cells in skin.

Katharina Hochheiser, Florian Wiede, Teagan Wagner, David Freestone, Matthias H Enders, Moshe Olshansky, Brendan Russ, Simone Nüssing, Emma Bawden, Asolina Braun, Annabell Bachem, Elise Gressier, Robyn McConville, Simone L Park, Claerwen M Jones, Gayle M Davey, David E Gyorki, David Tscharke, Ian A Parish, Stephen Turner, Marco J Herold, Tony Tiganis, Sammy Bedoui, Thomas Gebhardt,

Tissue-resident memory T cells (TRM cells) are key elements of tissue immunity. Here, we investigated the role of the regulator of T cell receptor and cytokine signaling, Ptpn2, in the formation and function of TRM cells in skin. Ptpn2-deficient CD8+ T cells displayed a marked defect in generating CD69+ CD103+ ... Read more >>

J Exp Med (The Journal of experimental medicine)
[2021, 218(6):]

Cited: 0 times

View full text PDF listing >>



Generating CAR T cells from tumor-infiltrating lymphocytes.

Jane K Mills, Melissa A Henderson, Lauren Giuffrida, Pasquale Petrone, Jennifer A Westwood, Phillip K Darcy, Paul J Neeson, Michael H Kershaw, David E Gyorki,

<b>Background:</b> Tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T-cell therapies have demonstrated promising, though limited, efficacy against melanoma. <b>Methods:</b> We designed a model system to explore the efficacy of dual specific T cells derived from melanoma patient TILs by transduction with a Her2-specific CAR. <b>Results:</b> Metastatic melanoma cells in ... Read more >>

Ther Adv Vaccines Immunother (Therapeutic advances in vaccines and immunotherapy)
[2021, 9:25151355211017119]

Cited: 0 times

View full text PDF listing >>



Second-line immunotherapy in patients with metastatic melanoma.

Annie Wong, David E Gyorki,

Lancet Oncol (The Lancet. Oncology)
[2021, 22(6):746-748]

Cited: 0 times

View full text PDF listing >>



Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).

Kristy Kummerow Broman, Tasha Hughes, Lesly Dossett, James Sun, Dennis Kirichenko, Michael J Carr, Avinash Sharma, Edmund K Bartlett, Amanda A G Nijhuis, John F Thompson, Tina J Hieken, Lisa Kottschade, Jennifer Downs, David E Gyorki, Emma Stahlie, Alexander van Akkooi, David W Ollila, Jill Frank, Yun Song, Giorgos Karakousis, Marc Moncrieff, Jenny Nobes, John Vetto, Dale Han, Jeffrey M Farma, Jeremiah L Deneve, Martin D Fleming, Matthew C Perez, Michael C Lowe, Roger Olofsson Bagge, Jan Mattsson, Ann Y Lee, Russell S Berman, Harvey Chai, Hidde M Kroon, Juri Teras, Roland M Teras, Norma E Farrow, Georgia Beasley, Jane Yuet Ching Hui, Lukas Been, Schelto Kruijff, Youngchul Kim, Syeda Mahrukh Hussnain Naqvi, Amod A Sarnaik, Vernon K Sondak, Jonathan S Zager,

<h4>Background</h4>For patients with sentinel lymph node (SLN)-positive cutaneous melanoma, the Second Multicenter Selective Lymphadenectomy trial demonstrated equivalent disease-specific survival (DSS) with active surveillance using nodal ultrasound versus completion lymph node dissection (CLND). Adoption and outcomes of active surveillance in clinical practice and in adjuvant therapy recipients are unknown.<h4>Methods</h4>In a retrospective ... Read more >>

Cancer (Cancer)
[2021, 127(13):2251-2261]

Cited: 0 times

View full text PDF listing >>



Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group.

Carol J Swallow, Dirk C Strauss, Sylvie Bonvalot, Piotr Rutkowski, Anant Desai, Rebecca A Gladdy, Ricardo Gonzalez, David E Gyorki, Mark Fairweather, Winan J van Houdt, Eberhard Stoeckle, Jae Berm Park, Markus Albertsmeier, Carolyn Nessim, Kenneth Cardona, Marco Fiore, Andrew Hayes, Dimitri Tzanis, Jacek Skoczylas, Samuel J Ford, Deanna Ng, John E Mullinax, Hayden Snow, Rick L Haas, Dario Callegaro, Myles J Smith, Toufik Bouhadiba, Silvia Stacchiotti, Robin L Jones, Thomas DeLaney, Christina L Roland, Chandrajit P Raut, Alessandro Gronchi, ,

<h4>Background</h4>Retroperitoneal soft tissue sarcomas comprise a heterogeneous group of rare tumors of mesenchymal origin that include several well-defined histologic subtypes. In 2015, the Transatlantic Australasian RPS Working Group (TARPSWG) published consensus recommendations for the best management of primary retroperitoneal sarcoma (RPS). Since then, through international collaboration, new evidence and knowledge ... Read more >>

Ann Surg Oncol (Annals of surgical oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The role of 18 F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective study.

Suren Subramaniam, Jason Callahan, Mathias Bressel, Michael S Hofman, Catherine Mitchell, Shona Hendry, Frederique L Vissers, Bernies Van der Hiel, Dakshesh Patel, Winan J Van Houdt, William W Tseng, David E Gyorki,

<h4>Background</h4>The role of <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup> F-FDG PET/CT) in the evaluation of retroperitoneal sarcomas is poorly defined. We evaluated the correlation of maximum standardized uptake value (SUVmax) with pathologic tumor grade in the surgical specimen of primary retroperitoneal dedifferentiated liposarcoma (DDLPS) and leiomyosarcoma (LMS).<h4>Methods</h4>Patients with the above ... Read more >>

J Surg Oncol (Journal of surgical oncology)
[2021, 123(4):1081-1087]

Cited: 0 times

View full text PDF listing >>



Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.

Kristy K Broman, Tasha M Hughes, Lesly A Dossett, James Sun, Michael J Carr, Dennis A Kirichenko, Avinash Sharma, Edmund K Bartlett, Amanda Ag Nijhuis, John F Thompson, Tina J Hieken, Lisa Kottschade, Jennifer Downs, David E Gyorki, Emma Stahlie, Alexander van Akkooi, David W Ollila, Jill Frank, Yun Song, Giorgos Karakousis, Marc Moncrieff, Jenny Nobes, John Vetto, Dale Han, Jeffrey Farma, Jeremiah L Deneve, Martin D Fleming, Matthew Perez, Kirsten Baecher, Michael Lowe, Roger Olofsson Bagge, Jan Mattsson, Ann Y Lee, Russell S Berman, Harvey Chai, Hidde M Kroon, Roland M Teras, Juri Teras, Norma E Farrow, Georgia M Beasley, Jane Yc Hui, Lukas Been, Schelto Kruijff, David Boulware, Amod A Sarnaik, Vernon K Sondak, Jonathan S Zager, ,

<h4>Background</h4>In sentinel lymph node (SLN)-positive melanoma, two randomized trials demonstrated equivalent melanoma-specific survival with nodal surveillance vs completion lymph node dissection (CLND). Patients with microsatellites, extranodal extension (ENE) in the SLN, or >3 positive SLNs constitute a high-risk group largely excluded from the randomized trials, for whom appropriate management remains ... Read more >>

J Am Coll Surg (Journal of the American College of Surgeons)
[2021, 232(4):424-431]

Cited: 0 times

View full text PDF listing >>



Diagnosis and management of cutaneous melanoma.

Victoria J Mar, H Peter Soyer, Alison Button-Sloan, Paul Fishburn, David E Gyorki, Margaret Hardy, Michael Henderson, John F Thompson,

<h4>Background</h4>In the field of melanoma, clinical trials evaluating the impact of sentinel node biopsy, completion lymph node dissection and adjuvant medical therapies on patient outcomes have provided evidence that has changed practice significantly over the past five years.<h4>Objective</h4>The aim of this article is to discuss key evidence that has informed new ... Read more >>

Aust J Gen Pract (Australian journal of general practice)
[2020, 49(11):733-739]

Cited: 0 times

View full text PDF listing >>



Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram".

R Olofsson Bagge, Michal Kicinski, Mark B Faries, David E Gyorki, Karolin Isaksson, Dimitrios Katsarelias, Serigne Lo, Marc Moncrieff, Andrew Spillane, Stefan Suciu, Alexander van Akkooi,

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, 38(27):3233-3234]

Cited: 1 time

View full text PDF listing >>



Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management.

Caroline G Watts, Andrea L Smith, Sam Robinson, Chiao-Han (Sharon) Chang, Chris Goumas, Helen Schmid, John W Kelly, Angela M Hong, Richard A Scolyer, Georgina V Long, Andrew J Spillane, Michael Henderson, David E Gyorki, Victoria J Mar, Rachael L Morton, Robyn PM Saw, Alex H Varey, Graham J Mann, John F Thompson, Anne E Cust,

<h4>Background and objectives</h4>In Australia, the uptake of the sentinel lymph node biopsy (SLNB) appears low despite clinical practice guideline recommendations. The aim of this study was to describe the knowledge and attitudes of general practitioners (GPs) to SLNB.<h4>Method</h4>GPs were recruited at an annual conference and a skin cancer skills workshop, ... Read more >>

Aust J Gen Pract (Australian journal of general practice)
[2020, 49(6):355-362]

Cited: 0 times

View full text PDF listing >>



Efficacy of immune checkpoint inhibitors for in-transit melanoma.

Emilia Nan Tie, Julia Lai-Kwon, Michael Alexander Rtshiladze, Lumine Na, James Bozzi, Tavis Read, Victoria Atkinson, George Au-Yeung, Georgina V Long, Grant A McArthur, Shahneen Sandhu, Robyn Saw, Euan Walpole, Alexander Menzies, Mark Smithers, David E Gyorki,

<h4>Background</h4>The efficacy of immune checkpoint inhibitors (ICI) in metastatic melanoma is well established. However, there are limited data regarding their efficacy in in-transit melanoma (ITM). This study assessed the efficacy of ICI in patients with ITM.<h4>Methods</h4>A retrospective review of patients with ITM commenced on an ICI between March 2013 and ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2020, 8(1):]

Cited: 0 times

View full text PDF listing >>



Systemic Therapy for Melanoma: ASCO Guideline.

Rahul Seth, Hans Messersmith, Varinder Kaur, John M Kirkwood, Ragini Kudchadkar, Jennifer Leigh McQuade, Anthony Provenzano, Umang Swami, Jeffrey Weber, Krishna C Alluri, Sanjiv Agarwala, Paolo A Ascierto, Michael B Atkins, Nancy Davis, Marc S Ernstoff, Mark B Faries, Jason S Gold, Samantha Guild, David E Gyorki, Nikhil I Khushalani, Michael O Meyers, Caroline Robert, Mario Santinami, Amikar Sehdev, Vernon K Sondak, Gilliosa Spurrier, Katy K Tsai, Alexander van Akkooi, Pauline Funchain,

<h4>Purpose</h4>To provide guidance to clinicians regarding the use of systemic therapy for melanoma.<h4>Methods</h4>ASCO convened an Expert Panel and conducted a systematic review of the literature.<h4>Results</h4>A systematic review, one meta-analysis, and 34 additional randomized trials were identified. The published studies included a wide range of systemic therapies in cutaneous and noncutaneous ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, 38(33):3947-3970]

Cited: 13 times

View full text PDF listing >>



Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study.

Frances Rapport, Andrea L Smith, Anne E Cust, Graham J Mann, Caroline G Watts, David E Gyorki, Michael Henderson, Angela M Hong, John W Kelly, Georgina V Long, Victoria J Mar, Rachael L Morton, Robyn Pm Saw, Richard A Scolyer, Andrew J Spillane, John F Thompson, Jeffrey Braithwaite,

<h4>Introduction</h4>Sentinel lymph node biopsy (SLNB) is a diagnostic procedure developed in the 1990s. It is currently used to stage patients with primary cutaneous melanoma, provide prognostic information and guide management. The Australian Clinical Practice Guidelines state that SLNB should be considered for patients with cutaneous melanoma >1 mm in thickness (or ... Read more >>

BMJ Open (BMJ open)
[2020, 10(2):e032636]

Cited: 0 times

View full text PDF listing >>



Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a single-centre study.

Rebekah Young, Hayden Snow, Shona Hendry, Catherine Mitchell, John Slavin, Stephen Schlicht, Lumine Na, Michael S Hofman, David E Gyorki,

<h4>Background</h4>Retroperitoneal sarcomas are rare soft tissue tumours accounting for 10-15% of soft tissue sarcomas. Patient prognosis and treatment recommendations (including extent of surgery and neoadjuvant strategies) are determined by the pre-operative histopathological subtype and grade obtained from biopsy and thus it is important to understand the accuracy of biopsy in ... Read more >>

ANZ J Surg (ANZ journal of surgery)
[2020, 90(4):497-502]

Cited: 0 times

View full text PDF listing >>



Accumulation of CD103+ CD8+ T cells in a cutaneous melanoma micrometastasis.

Katharina Hochheiser, Han Xian Aw Yeang, Teagan Wagner, Candani Tutuka, Andreas Behren, Jason Waithman, Christopher Angel, Paul J Neeson, Thomas Gebhardt, David E Gyorki,

Objective:The immune system can halt cancer progression by suppressing outgrowth of clinically occult micrometastases in a state of cancer-immune equilibrium. Cutaneous melanoma provides a unique opportunity to study the immune contexture of such lesions, as miniscule skin metastases are accessible to clinical inspection and diagnostic biopsy. Methods:Here, we analysed by ... Read more >>

Clin Transl Immunology (Clinical & translational immunology)
[2019, 8(12):e1100]

Cited: 3 times

View full text PDF listing >>



Locoregional melanoma: identifying optimal care in a rapidly changing landscape.

David E Gyorki, Jonathan S Zager,

Melanoma Manag (Melanoma management)
[2019, 6(3):MMT22]

Cited: 0 times

View full text PDF listing >>



The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre.

Emilia Nan Tie, Lumine H Na, Rodney J Hicks, John Spillane, David Speakman, Michael A Henderson, David E Gyorki,

BACKGROUND:Patients with in-transit melanoma metastases (ITM) experience a diverse spectrum of clinical presentations and a highly variable disease course. There is no standardized treatment protocol for these patients due to the limited data comparing treatment modalities for ITM. This is the first study to describe the disease trajectory and natural ... Read more >>

Ann Surg Oncol (Annals of surgical oncology)
[2019, 26(13):4673-4680]

Cited: 0 times

View full text PDF listing >>



Skin colonization with beta papilloma virus drives tissue immunity and resistance to squamous cell cancer.

Katharina Hochheiser, David E Gyorki, Thomas Gebhardt,

Immunol Cell Biol (Immunology and cell biology)
[2020, 98(1):9-11]

Cited: 1 time

View full text PDF listing >>



Systemic therapies for unresectable locoregional melanoma: a significant area of need.

Emilia Nan Tie, Julia E Lai-Kwon, David E Gyorki,

Immune checkpoint inhibitors and BRAF-MEK inhibitors have revolutionized the management and prognosis of patients with metastatic melanoma. However, there is minimal evidence to guide their incorporation into current treatment paradigms for unresectable stage III disease. The era of effective systemic therapies has prompted a discussion about what constitutes unresectable disease. ... Read more >>

Melanoma Manag (Melanoma management)
[2019, 6(3):MMT25]

Cited: 2 times

View full text PDF listing >>



An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?

Jennifer S Downs, David E Gyorki,

Management of later stage melanoma has undergone significant changes. Sentinel node biopsy has long been an accepted method of staging, but two recent randomized-controlled trials have provided an evidence base for decision making about completion lymphadenectomy. They showed no survival advantage in further surgery for patients with positive sentinel node ... Read more >>

Melanoma Manag (Melanoma management)
[2019, 6(3):MMT24]

Cited: 0 times

View full text PDF listing >>



Characterizing high-grade serous papillary carcinoma of tunica vaginalis.

Liang G Qu, Jiasian Teh, Catherine Mitchell, David E Gyorki, Rodney J Hicks, Declan G Murphy,

Serous carcinomas of the testis or para-testis are extremely rare tumors of Mullerian type. We report a case of high-grade serous papillary carcinoma of the tunica vaginalis, treated with radical orchiectomy and hemi-scrotectomy after being referred for a rapidly growing painless scrotal mass. In addition to negative testicular tumor markers, ... Read more >>

Urol Case Rep (Urology case reports)
[2019, 26:100949]

Cited: 0 times

View full text PDF listing >>



ASO Author Reflections: The Impacts of a Negative Sentinel Lymph Node on Quality of Life.

Sarah Banting, David E Gyorki,

Ann Surg Oncol (Annals of surgical oncology)
[2019, 26(Suppl 3):651-652]

Cited: 0 times

View full text PDF listing >>



Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Rodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, Richard A Scolyer, Michael T Tetzlaff, Robert Antdbacka, Charlotte Ariyan, Roland Bassett, Brett Carter, Adil Daud, Mark Faries, Leslie A Fecher, Keith T Flaherty, Jeffrey E Gershenwald, Omid Hamid, Angela Hong, John M Kirkwood, Serigne Lo, Kim Margolin, Jane Messina, Michael A Postow, Helen Rizos, Merrick I Ross, Elisa A Rozeman, Robyn P M Saw, Vernon Sondak, Ryan J Sullivan, Janis M Taube, John F Thompson, Bart A van de Wiel, Alexander M Eggermont, Michael A Davies, , Paolo A Ascierto, Andrew J Spillane, Alexander C J van Akkooi, Jennifer A Wargo, Christian U Blank, Hussein A Tawbi, Georgina V Long,

Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of response and toxicity. Neoadjuvant therapy for regional metastases might improve operability and clinical outcomes over upfront ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2019, 20(7):e378-e389]

Cited: 29 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0851 s